Skip to main content
SpringerLink
Log in

New treatments for Hodgkin’s disease

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Four of five patients with Hodgkin’s disease (HD) will be cured with modern treatment strategies, depending on stage and risk factor profile. In early stage favorable HD, cure rates are greater than 90% with extended field (EF) irradiation, the standard treatment. However, the concept of EF irradiation therapy is being abandoned by most study groups because of the recognition of fatal long-term effects, especially the high rates of second solid tumors. Newer approaches include mild chemotherapy combined with involved field (IF) irradiation to control occult disease. Combined modality is the treatment of choice in early stages unfavorable (intermediate) HD, in which EF irradiation is substituted by IF irradiation. In the last three decades, because of the high relapse rates (30%–50%) after first-line polychemotherapy, the standard regimens were often modified. However, until recently, these efforts could not change the relatively poor outcome for patients with advanced stage disease. The introduction of a new dose-intensified regimen (BEACOPP) has significantly improved the prognosis for patients with advanced HD. Patients who relapse after radiation therapy alone for early stage HD have satisfactory results with combination chemotherapy and are not considered as candidates for high-dose chemotherapy with autologous stem cell transplantation. For patients with relapsed HD after combination chemotherapy, the data support the use of high-dose chemotherapy with autologous stem cell transplantation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Carde P, Burger JM, Henry-Amar M: Clinical stages I and II Hodgkin’s disease: a specifically tailored therapy according to prognostic factors. J Clin Oncol 1988, 6:239–248.

    PubMed  CAS  Google Scholar 

  2. Loeffler M, Pfreundschuh M, Rühl U: Risk factor adapted treatment of Hodgkin’s lymphoma: strategies and perspectives. Recent Results Cancer Res 1989, 117:142–162.

    PubMed  CAS  Google Scholar 

  3. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 1998, 339:1506–1514.

    Article  PubMed  CAS  Google Scholar 

  4. Sarris A, Kliche K, Pethambaram P, et al.: Interleukin-10 levels are often elevated in serum of adults with Hodgkin’s disease and are associated with inferior failure-free survival. Ann Oncol 1999, 10:433–439.

    Article  PubMed  CAS  Google Scholar 

  5. von Wasielewski R, Seth S, Franklin J, et al.: Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin’s disease allowing for known prognostic factors. Blood 2000, 95: 1207–1213.

    Google Scholar 

  6. Duhmke E, Franklin J, Pfreundschuh M, et al.: Low-dose radiation is sufficient for the noninvolved extendedfield treatment in favorable early-stage Hodgkin’s disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol 2001 19:2905–2914.

    PubMed  CAS  Google Scholar 

  7. Carde P, Noordijk E, Hagenbeek A: Superiority of EBVP chemotherapy in combination with involved field irradiation over subtotal nodal irradiation in favorable clinical stage I-II Hodgkin’s disease: the EORTC-GPMC H7F randomized trial. Proc Am Soc Clin Oncol 1997, 16:13.

    Google Scholar 

  8. Diehl V, Sieber M, Rüffer U: Treatment of early-stage Hodgkin’s disease: considerations in the use of chemotherapy. Annual Meeting of American Society of Clinical Oncology, Los Angeles, CA, 1998.

  9. Engert A, Schiller P, Pfistner B, et al.: Involved field (IF) radiotherapy is as effective as extended field (EF) radiotherapy after 2 cycles of COPP/ABVD in patients (pts) with intermediate-stage Hodgkin’s disease (HD): randomized multicenter study. Blood 2001, 98:3199a.

    Google Scholar 

  10. De Vita VT Jr, Simon RM, Hubbard G, et al.: Curability of advanced Hodgkin’s disease with chemotherapy: longterm follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980, 92:587–595.

    Google Scholar 

  11. Bonadonna G, Zucali R, Monfardini S, et al.: Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975, 36:252–260.

    Article  PubMed  CAS  Google Scholar 

  12. Canellos GP, Anderson JR, Propert KJ, et al.: Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992, 327:1478–1485.

    Article  PubMed  CAS  Google Scholar 

  13. Connors JM, Klimo P, Adams G, et al.: Treatment of advanced Hodgkin’s disease with chemotherapy— comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group. J Clin Oncol 1997, 15:1638–1645.

    PubMed  CAS  Google Scholar 

  14. Sieber M, Rueffer U, Tesch H: Rapidly alternating COPP+ABV+IMEP CAI is equally effective as alternating COPP+ABVD CA for Hodgkin’s disease: final results of two randomised trials for intermediate HD5 protocol) and advanced HD6 protocol stages.tLeuk Lymphoma 1998, 29:93.

    Google Scholar 

  15. Carde P, MacKintosh F, Rosenberg S, et al.: A dose and time response analysis of the treatment of Hodgkin’s disease with MOPP chemotherapy. J Clin Oncol 1983, 1:146–153.

    PubMed  CAS  Google Scholar 

  16. Bartlett N, Rosenberg S, Hoppe R, et al.: Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin’s disease: a preliminary report. J Clin Oncol 1995, 13:1080–1088.

    PubMed  CAS  Google Scholar 

  17. Diehl V, Franklin J, Hasenclever D, et al.: BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin’s lymphoma: interim report from a trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 1998, 16:3810–3819.

    PubMed  CAS  Google Scholar 

  18. Diehl V, Franklin J, Paulus U, et al.: BEACOPP chemotherapy with dose escalation in advanced Hodgkin’s disease: final analysis of the German Hodgkin Lymphoma Study Group HD9 randomized trial. Blood 2001, 98:3202a.

    Google Scholar 

  19. Loeffler M, Brosteanu O, Hasenclever D, et al.: Metaanalysis of chemotherapy versus combined modality treatment trials in Hodgkin’s disease. International Database on Hodgkin’s Disease Overview Study Group. J Clin Oncol 1998, 16:818–829.

    PubMed  CAS  Google Scholar 

  20. Cannellos G, Young RC, De Vita VD: Combination chemotherapy for advanced Hodgkin’s disease in relapse following extensive radiotherapy. Clin Pharmacol Ther 1972, 13:750–758.

    PubMed  CAS  Google Scholar 

  21. Santoro A, Viviani S, Villarreal C, et al.: Salvage chemotherapy in Hodgkin’s disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP. Cancer Treat Rep 1986, 70:343–351.

    PubMed  CAS  Google Scholar 

  22. Longo D, Duffey P, Young R, et al.: Conventionaldose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy: the low probability for cure. J Clin Oncol 1992, 10:210–219.

    PubMed  CAS  Google Scholar 

  23. Santoro A, Viviani S, Valagussa P, et al.: CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin’s disease. Semin Oncol 1986, 13:23–32.

    PubMed  CAS  Google Scholar 

  24. Schulman P, McCarroll K, Cooper M, et al.: Phase II study of MOPLACE chemotherapy for patients with previously treated Hodgkin’s disease: a CALGB study. Med Pediatr Oncol 1990, 18:482–490.

    Article  PubMed  CAS  Google Scholar 

  25. Pfreundschuh M, Rueffer U, Lathan B, et al.: Dexa-BEAM in patients with Hodgkin’s disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin’s Disease Study Group. J Clin Oncol 1994, 12:580–592.

    PubMed  CAS  Google Scholar 

  26. Hagemeister F, Tannir N, McLaughlin P, et al.: MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin’s disease. J Clin Oncol 1987, 5:556–563.

    PubMed  CAS  Google Scholar 

  27. Rodriguez J, Rodriguez M, Fayad L, et al.: ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin’s disease. Blood 1999, 93:3632–3641.

    PubMed  CAS  Google Scholar 

  28. Pfreundschuh MG, Schoppe WD, Fuchs R: Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin’s disease refractory to cyclophosphamide, vincristine, procarbacine, and prednisone (COPP) and doxorubicine, bleomycin, vinblastine, and darcarbazine (ABVD): a multi-center trial of the German Hodgkin’s study group. Cancer Treat Rep 1987, 71:1203–1212.

    PubMed  CAS  Google Scholar 

  29. Cowill R, Crump M, Couture F: Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin’s disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol 1995, 13:396–403.

    Google Scholar 

  30. Velasquez WS, Jagannath S, Hagemeister FB: Dexamethasone, high-dose ara-C and cisplatin as salvage treatment for relapsing Hodgkin’s disease. Proc Am Soc Hematol 1986, 68:242–249.

    Google Scholar 

  31. Josting A, Reiser M, Rueffer U, et al.: Treatment of primary progressive Hodgkin’s and aggressive non-Hodgkin’s lymphoma: is there a chance for cure? J Clin Oncol 2000, 18:332–339.

    PubMed  CAS  Google Scholar 

  32. Sweetenham J, Taghipour G, Milligan D, et al.: High-dose therapy and autologous stem cell rescue for patients with Hodgkin’s disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1997, 20:745–751.

    Article  PubMed  CAS  Google Scholar 

  33. Bierman P, Bagin R, Jagannath S, et al.: High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin’s disease: long-term follow-up in 128 patients. Ann Oncol 1993, 4:767–774.

    PubMed  CAS  Google Scholar 

  34. Jones R, Piantadosi S, Mann R, et al.: High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin’s disease. J Clin Oncol 1990, 8:527–534.

    PubMed  CAS  Google Scholar 

  35. Josting A, Katay I, Rueffer U, et al.: Favorable outcome of patients with relapsed or refractory Hodgkin’s disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (dexa-BEAM). Ann Oncol 1998, 9:289–295.

    Article  PubMed  CAS  Google Scholar 

  36. Linch D, Winfield D, Goldstone A, et al.: Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet 1993, 341:1051–1054.

    Article  PubMed  CAS  Google Scholar 

  37. Schmitz N, Sextro M, Pfistner B, et al.: HDR-1: high-dose therapy (HDT) followed by hematopoietic stem cell transplantation (HSCT) for relapsed chemosensitive Hodgkin’s disease (HD): final results of a randomized GHSG and EBMT trial (HD-R1). Proc ASCO 1999:18a.

  38. Josting C, Rudolph M, Mapara Y, et al.: Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin’s and aggressive non-Hodgkin’s lymphoma: results of a multicenter phase-II study. Blood 2001, 98:2848a.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. First Department of Internal Medicine, University Hospital Cologne, Joseph-Stelzmann-Str. 9, 50924, Cologne, Germany

    Jan-Peter Glossmann MD, Andreas Josting MD & Volker Diehl MD

Authors
  1. Jan-Peter Glossmann MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andreas Josting MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Volker Diehl MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Glossmann, JP., Josting, A. & Diehl, V. New treatments for Hodgkin’s disease. Curr. Treat. Options in Oncol. 3, 283–290 (2002). https://doi.org/10.1007/s11864-002-0028-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-002-0028-x

Keywords

Search

Navigation